Balancing the risks and benefits of infliximab in the treatment of inflammatory bowel disease.
Patients with moderate to severely active Crohn's disease treated with infliximab may have a small but real risk of developing severe infections, opportunistic infections, and non-Hodgkin's lymphoma.
Sandborn
W J
WJ
Inflammatory Bowel Disease Clinic, Division of Gastroenterology and Hepatology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA. sandborn.william@mayo.edu
Loftus
E V
EV
D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D003424:Crohn Disease / Q000188:drug therapy*; D005765:Gastrointestinal Agents / Q000009:adverse effects*; D006801:Humans; D000069285:Infliximab; D008228:Lymphoma, Non-Hodgkin / Q000139:chemically induced; D009894:Opportunistic Infections / Q000139:chemically induced; D012307:Risk Factors
D000911:Antibodies, Monoclonal; D005765:Gastrointestinal Agents; D000069285:Infliximab